Vanda Pharmaceuticals Inc... (VNDA)
NASDAQ: VNDA
· Real-Time Price · USD
4.53
0.05 (1.12%)
At close: Sep 11, 2025, 11:54 AM
Vanda Pharmaceuticals Revenue Breakdown
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Fanapt Revenue | 29.29M | 23.55M | 26.65M | 23.92M | 23.15M | 20.58M | 22.6M | 21.32M | 24.08M | 22.88M | 24.38M | 23.98M | 23.2M | 23.16M | 23.95M | 24.48M | 23.39M | 23.33M | 23.48M | 20.69M | 20.65M | 22.66M | 22.33M | 21.9M | 21.23M | 18.76M | 19.21M | 19.3M | 18.17M | 19.27M | 19.06M | 19.55M | 17.23M | 18.95M | 19.77M | 18.57M | 17.06M | 16.71M | 16.66M | 17.57M | 14.69M |
| Fanapt Revenue Growth | +24.42% | -11.65% | +11.41% | +3.32% | +12.49% | -8.94% | +6.02% | -11.47% | +5.22% | -6.15% | +1.66% | +3.37% | +0.18% | -3.29% | -2.17% | +4.66% | +0.27% | -0.66% | +13.49% | +0.21% | -8.90% | +1.49% | +1.99% | +3.16% | +13.16% | -2.37% | -0.48% | +6.25% | -5.69% | +1.10% | -2.52% | +13.44% | -9.06% | -4.14% | +6.45% | +8.84% | +2.12% | +0.26% | -5.14% | +19.57% | n/a |
| Hetlioz Revenue | 16.19M | 20.87M | 20.04M | 17.87M | 18.71M | 20.05M | 21.07M | 17.5M | 21.98M | 39.62M | 40.1M | 41.34M | 41.19M | 37.03M | 44.07M | 45.62M | 44.51M | 39.34M | 44.17M | 39.62M | 41.56M | 35.34M | 38.6M | 37.59M | 37.84M | 28.96M | 29.92M | 28.05M | 25.42M | 25.01M | 22.28M | 22.51M | 20.18M | 19.3M | 18.71M | 17.46M | 16.2M | 15.14M | 11.68M | 10.02M | 7.46M |
| Hetlioz Revenue Growth | -22.42% | +4.13% | +12.17% | -4.48% | -6.71% | -4.84% | +20.41% | -20.38% | -44.52% | -1.21% | -2.99% | +0.36% | +11.23% | -15.97% | -3.39% | +2.48% | +13.13% | -10.93% | +11.49% | -4.68% | +17.62% | -8.45% | +2.69% | -0.65% | +30.66% | -3.23% | +6.70% | +10.31% | +1.65% | +12.26% | -1.01% | +11.52% | +4.60% | +3.10% | +7.19% | +7.77% | +6.99% | +29.63% | +16.62% | +34.28% | n/a |
Operating Expense Breakdown
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 64.62M | 50.08M | 39.28M | 37.57M | 39.47M | 30.09M | 23.61M | 24.77M | 28.4M | 36.1M | 32.78M | 29.85M | 33M | 40.85M | 33.45M | 32.46M | 28.35M | 29.8M | 35.57M | 34M | 33.92M | 37.02M | 37.02M | 30.22M | 31.47M | 31.03M | 24.92M | 26.05M | 27.96M | 26.82M | 31.05M | 31.12M | 31.37M | 30.3M | 23.91M | 21.91M | 24.68M | 29.29M | 28.88M | 18.46M | 18.39M | 18.81M |
| Selling, General, and Administrative Revenue Growth | +29.02% | +27.50% | +4.55% | -4.82% | +31.21% | +27.41% | -4.66% | -12.79% | -21.34% | +10.13% | +9.81% | -9.54% | -19.21% | +22.13% | +3.05% | +14.50% | -4.87% | -16.23% | +4.62% | +0.25% | -8.38% | +0.01% | +22.49% | -3.96% | +1.41% | +24.50% | -4.32% | -6.84% | +4.24% | -13.61% | -0.24% | -0.79% | +3.54% | +26.73% | +9.12% | -11.24% | -15.73% | +1.42% | +56.47% | +0.39% | -2.23% | n/a |
| Research and Development Revenue | 21.99M | 35.71M | 19.84M | 16.78M | 16.66M | 21.15M | 24.34M | 16.6M | 16.65M | 19.24M | 18.45M | 24.86M | 21.49M | 20.97M | 19.33M | 19.65M | 20.25M | 16.13M | 14.85M | 12.3M | 12.9M | 15.53M | 13.07M | 11.35M | 10.95M | 13.28M | 12.92M | 11.39M | 9.87M | 9.42M | 10.15M | 10.18M | 7.65M | 10.57M | 7.61M | 7.29M | 6.7M | 7.55M | 8.75M | 9.97M | 5.95M | 4.48M |
| Research and Development Revenue Growth | -38.42% | +80.00% | +18.26% | +0.69% | -21.24% | -13.09% | +46.62% | -0.28% | -13.46% | +4.24% | -25.76% | +15.67% | +2.48% | +8.47% | -1.64% | -2.94% | +25.52% | +8.63% | +20.74% | -4.69% | -16.90% | +18.76% | +15.22% | +3.63% | -17.53% | +2.75% | +13.45% | +15.45% | +4.78% | -7.27% | -0.24% | +33.08% | -27.62% | +38.78% | +4.39% | +8.87% | -11.23% | -13.71% | -12.30% | +67.74% | +32.78% | n/a |